In Poland, the diagnosis of EGFR gene mutations is performed in patients with non-squamous cell carcinoma and, until recently, only in patients with advanced NSCLC (due to the reimbursement regulations for EGFR tyrosine kinase inhibitors therapy). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.